2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
16
Thoracic
12
Gynecologic
11
Genitourinary
11
Other solid neoplasm
9
Head & Neck
7
Breast
5
Dermatologic
3
Endocrine
2
Tumor-Agnostic
1
Sarcoma
1
Plasma cell
1
NET
1
Lymphoid
1
CNS
1
Conditions
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Gestational Trophoblastic Disease
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoid Tumor
1
Interventions
lutetium Lu 177 dotatate
48
Everolimus
40
Magnetic Resonance Spectroscopy
21
lanreotide
17
Temozolomide
17
gallium Ga 68 dotatate
15
Octreotide
15
pembrolizumab
13
Nivolumab
13
surufatinib
12
Capecitabine
12
cabozantinib
11
177Lu-octreotide, DOTA(0)-Tyr(3)-
11
Sunitinib
10
pasireotide
9
Specimen Handling
9
Positron Emission Tomography Computed Tomography
9
Lutetium-177
9
3-Iodobenzylguanidine
9
Ga(III)-DOTATOC
8
Carboplatin
8
telotristat ethyl
6
copper dotatate CU-64
6
amino-acid, glucose, and electrolyte solution
6
Somatostatin
6
Ipilimumab
6
Fluorodeoxyglucose F18
6
Etoposide
6
Cisplatin
6
90Y-octreotide, DOTA-Tyr(3)-
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
zimberelimab
×
NET
×
Clear all
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled